other material
confidence high
sentiment neutral
materiality 0.85
CERo Therapeutics enters $20.6M stock purchase agreement and shareholders approve reverse split and equity plan
CERO THERAPEUTICS HOLDINGS, INC.
- Entered into a purchase agreement with Keystone Capital Partners, LLC to sell up to $20,589,384.23 of common stock.
- Shareholders approved a reverse stock split at a ratio between 1:25 and 1:150, set by the board.
- Shareholders approved issuance of shares upon conversion of Series C Preferred and exercise of warrants from September 2024.
- Shareholders approved an increase of 20,845,391 shares under the 2024 Equity Incentive Plan.
- Company had previously sold 23,377,921 shares for $4.41 million under the prior purchase agreement.